CN110325536A - Janus激酶抑制剂的晶体形式 - Google Patents

Janus激酶抑制剂的晶体形式 Download PDF

Info

Publication number
CN110325536A
CN110325536A CN201780086980.3A CN201780086980A CN110325536A CN 110325536 A CN110325536 A CN 110325536A CN 201780086980 A CN201780086980 A CN 201780086980A CN 110325536 A CN110325536 A CN 110325536A
Authority
CN
China
Prior art keywords
crystal form
composition
crystal
peak
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780086980.3A
Other languages
English (en)
Chinese (zh)
Inventor
神谷幸宏
下山典昭
大仓隆平
野路悟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to CN202511159370.4A priority Critical patent/CN121045220A/zh
Publication of CN110325536A publication Critical patent/CN110325536A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780086980.3A 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式 Pending CN110325536A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511159370.4A CN121045220A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
US62/437262 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511159370.4A Division CN121045220A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式

Publications (1)

Publication Number Publication Date
CN110325536A true CN110325536A (zh) 2019-10-11

Family

ID=60991475

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780086980.3A Pending CN110325536A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式
CN202511159370.4A Pending CN121045220A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511159370.4A Pending CN121045220A (zh) 2016-12-21 2017-12-20 Janus激酶抑制剂的晶体形式

Country Status (13)

Country Link
US (1) US11339181B2 (https=)
EP (1) EP3559003B1 (https=)
JP (3) JP2020502224A (https=)
KR (1) KR102788829B1 (https=)
CN (2) CN110325536A (https=)
AU (1) AU2017380213B2 (https=)
BR (1) BR112019012210A2 (https=)
CA (1) CA3044771A1 (https=)
ES (1) ES2926986T3 (https=)
IL (1) IL267393B2 (https=)
MX (1) MX386181B (https=)
TW (1) TWI822666B (https=)
WO (1) WO2018117153A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111606929A (zh) * 2020-06-30 2020-09-01 苏州明锐医药科技有限公司 德高替尼的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017384317C1 (en) 2016-12-21 2022-06-30 Japan Tobacco Inc. PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
JP7807247B2 (ja) * 2021-02-05 2026-01-27 ロート製薬株式会社 シェーグレン症候群治療剤
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
WO2024180493A1 (en) * 2023-02-28 2024-09-06 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053936A1 (en) * 2008-04-11 2011-03-03 Paul Robert Eastwood substituted spiro[cycloalkyl-1,3'-indol]-2'(1'h)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
US20110136778A1 (en) * 2009-07-31 2011-06-09 Japan Tobacco Inc. Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof
WO2011114275A1 (en) * 2010-03-15 2011-09-22 University Of Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
CN102458411A (zh) * 2009-05-22 2012-05-16 因塞特公司 作为jak抑制剂的3-[4-(7h-吡咯并[2，3-d]嘧啶-4-基)-1h-吡唑-1-基]辛烷-或庚烷-腈
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
CN107709337A (zh) * 2015-07-07 2018-02-16 日本烟草产业株式会社 7H‑吡咯并[2，3‑d]嘧啶衍生物的制备方法和其中间体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090296332A1 (en) * 2005-07-07 2009-12-03 Thomson Licensing Flat-Screen Display System With Corresponding Sleeves

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053936A1 (en) * 2008-04-11 2011-03-03 Paul Robert Eastwood substituted spiro[cycloalkyl-1,3'-indol]-2'(1'h)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
CN102458411A (zh) * 2009-05-22 2012-05-16 因塞特公司 作为jak抑制剂的3-[4-(7h-吡咯并[2，3-d]嘧啶-4-基)-1h-吡唑-1-基]辛烷-或庚烷-腈
US20110136778A1 (en) * 2009-07-31 2011-06-09 Japan Tobacco Inc. Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof
WO2011114275A1 (en) * 2010-03-15 2011-09-22 University Of Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
CN107709337A (zh) * 2015-07-07 2018-02-16 日本烟草产业株式会社 7H‑吡咯并[2，3‑d]嘧啶衍生物的制备方法和其中间体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ATSUO TANIMOTO ET AL.: "Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo", 《INFLAMM. RES.》 *
MAARTEN VAN DEN BUUSE ET AL.: "Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition", 《THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 *
吕扬 等: "《晶型药物》", 31 October 2009, 人民卫生出版社 *
李亦菲: "基于烯酰基乙酰胺的杂环化反应研究", 《中国优秀博硕士学位论文全文数据库（博士）工程科技I辑》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111606929A (zh) * 2020-06-30 2020-09-01 苏州明锐医药科技有限公司 德高替尼的制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法

Also Published As

Publication number Publication date
EP3559003A1 (en) 2019-10-30
RU2019122566A (ru) 2021-01-22
CA3044771A1 (en) 2018-06-28
IL267393B1 (en) 2023-03-01
RU2019122566A3 (https=) 2021-12-22
EP3559003B1 (en) 2022-08-24
IL267393A (en) 2019-08-29
IL267393B2 (en) 2023-07-01
CN121045220A (zh) 2025-12-02
KR102788829B1 (ko) 2025-03-31
KR20190092440A (ko) 2019-08-07
AU2017380213B2 (en) 2022-01-06
MX2019007462A (es) 2019-08-29
JP2023024729A (ja) 2023-02-16
MX386181B (es) 2025-03-18
AU2017380213A1 (en) 2019-05-23
ES2926986T3 (es) 2022-10-31
BR112019012210A2 (pt) 2019-11-12
JP2024161449A (ja) 2024-11-19
JP2020502224A (ja) 2020-01-23
TW201829423A (zh) 2018-08-16
WO2018117153A1 (en) 2018-06-28
US20200017527A1 (en) 2020-01-16
US11339181B2 (en) 2022-05-24
TWI822666B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
US11591318B2 (en) Bipyrazole derivatives as JAK inhibitors
US11401279B2 (en) Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11753406B2 (en) Salts of a PD-1/PD-L1 inhibitor
EP3774791B1 (en) Heterocyclic compounds as immunomodulators
CN110325536A (zh) Janus激酶抑制剂的晶体形式
EP2640725A1 (en) Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2022017446A1 (zh) Akt抑制剂的单位剂量组合物
EP3847175B1 (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
RU2838992C2 (ru) Кристаллические формы ингибитора янус-киназы
US20230192710A1 (en) Jak inhibitor compound and use thereof
HK40107642A (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
HK40097413A (en) Heterocyclic compounds as immunomodulators
HK40057216A (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
HK40057216B (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
TW202313014A (zh) 作為ｐｄ－ｌ１相互作用的免疫調節劑的雜環化合物
WO2021158891A1 (en) Salts and solid forms and processes of preparing a pi3k inhibitor
HK40047182B (en) Heterocyclic compounds as immunomodulators
HK40047182A (en) Heterocyclic compounds as immunomodulators
BR122024025362A2 (pt) Formas cristalinas de um inibidor de janus cinase, composição farmacêutica compreendendo as ditas formas cristalinas, seu uso e métodos de medição

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination